Expression of angiogenic factors and tumor progression in human neuroblastoma

被引:25
作者
Komuro, H [1 ]
Kaneko, S [1 ]
Kaneko, M [1 ]
Nakanishi, Y [1 ]
机构
[1] Univ Tsukuba, Inst Clin Med, Dept Pediat Surg, Tsukuba, Ibaraki 3058575, Japan
基金
日本学术振兴会;
关键词
neuroblastoma; vascular endothelial growth factor-A; vascular endothelial growth factor-C; basic fibroblast growth factor; platelet-derived endothelial growth factor/thymidine phosphorylase;
D O I
10.1007/s004320100293
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: The growth and metastasis of malignant tumors is largely dependent on angiogenesis. Angiogenic factors produced by tumor cells are known to promote tumor angiogenesis. The aim of this study was to investigate which angiogenic factor is the most important in the progression of neuroblastoma (NB). Procedure: The relative expression levels of vascular endothelial growth factor-A (VEGF-A), VEGF-C, basic fibroblast growth factor (bFGF), and platelet-derived endothelial growth factor (PD-ECGF/TP) were studied in 28 NB tumor specimens by real-time quantitative reverse transcriptase/polymerase chain reaction (RT-PCR). The relationships between the expression of these four angiogenic factors and stage, patient age, primary site, MYCN copy number, and lymph node metastasis were analyzed. Results: High VEGF-A expression was correlated with stage 4 disease (blood-borne metastasis). No relationship between VEGF-A expression and age, primary site, MYCN copy number, or lymph node metastasis was found. The expression of VEGF-C, bFGF, or PD-ECGF/TP showed no correlation with stage, age, primary site, MYCN copy number, or lymph node metastasis. Conclusions: Our findings suggest that VEGF-A, but not VEGF-C, bFGF, or PD-ECGF/TP, may be associated with progression of NB. VEGF-A could be a target for antiangiogenic therapy for disseminated NB.
引用
收藏
页码:739 / 743
页数:5
相关论文
共 30 条
[1]
Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer [J].
Anan, K ;
Morisaki, T ;
Katano, M ;
Ikubo, A ;
Kitsuki, H ;
Uchiyama, A ;
Kuroki, S ;
Tanaka, M ;
Torisu, M .
SURGERY, 1996, 119 (03) :333-339
[2]
André T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO
[3]
2-5
[4]
REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].
BRODEUR, GM ;
PRITCHARD, J ;
BERTHOLD, F ;
CARLSEN, NLT ;
CASTEL, V ;
CASTLEBERRY, RP ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
HEDBORG, F ;
KANEKO, M ;
KEMSHEAD, J ;
LAMPERT, F ;
LEE, REJ ;
LOOK, AT ;
PEARSON, ADJ ;
PHILIP, T ;
ROALD, B ;
SAWADA, T ;
SEEGER, RC ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477
[5]
Eggert A, 2000, CLIN CANCER RES, V6, P1900
[6]
VEGF: an update on biological and therapeutic aspects [J].
Farrara, N .
CURRENT OPINION IN BIOTECHNOLOGY, 2000, 11 (06) :617-624
[7]
Fujimoto J, 1999, CANCER RES, V59, P3041
[8]
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J].
Hanahan, D ;
Folkman, J .
CELL, 1996, 86 (03) :353-364
[9]
Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis [J].
Heaney, AP ;
Horwitz, GA ;
Wang, ZY ;
Singson, R ;
Melmed, S .
NATURE MEDICINE, 1999, 5 (11) :1317-1321
[10]
HETEROGENEITY OF HUMAN NEUROBLASTOMA CELL-LINES IN THEIR PROLIFERATIVE RESPONSES TO BASIC FGF, NGF, AND EGF - CORRELATION WITH EXPRESSION OF GROWTH-FACTORS AND GROWTH-FACTOR RECEPTORS [J].
JANET, T ;
LUDECKE, G ;
OTTEN, U ;
UNSICKER, K .
JOURNAL OF NEUROSCIENCE RESEARCH, 1995, 40 (06) :707-715